All Pharmaceutical Microbiology articles – Page 3
-
NewsMedications change our gut microbiome in predictable ways
A study shows that many of the changes to the gut microbiome are driven by competition for nutrients – medications reduce certain bacterial populations and change the availability of nutrients, and the bacteria most able to capitalize on those changes are the ones to survive.
-
NewsSugar transporter discovery offers promising avenue for improving antibiotic efficacy
Scientists have recently demonstrated that aminoglycosides enter bacteria by using sugar transporters. They have also successfully doubled the number of transporters, even in the most resistant Escherichia coli strains, thus improving antibiotics’ penetration rate and efficacy.
-
NewsStudy in Europe: monoclonal antibodies effectively prevent respiratory syncytial virus in infants
Data from Belgium, Portugal and Spain show that immunisation of children after birth reduced the risk of hospitalization due to RSV infection by almost 80%.
-
NewsProtecting infants against respiratory syncytial virus this winter — ECDC issues advice
ECDC has issued rapid scientific advice for policymakers and public health authorities on ways to mitigate the impact of RSV disease among infants through immunisation and to support intensified efforts to protect them from RSV across Europe.
-
NewsBiomedical Sciences researcher receives nearly $7 million in federal grants to fight STIs
Cynthia Nau Cornelissen, a Distinguished University Professor and associate director of the Institute for Biomedical Sciences at Georgia State University, has received nearly $7 million in two, five-year federal grants to develop vaccines and therapeutics to combat sexually transmitted infections (STIs).
-
NewsKorea University College of Medicine’s Vaccine Innovation Center selected as lead institution for 2025 Korea-ARPA-H Health Security Project
The Vaccine Innovation Center at Korea University College of Medicine has been selected as the lead institution for a health security research initiative under the Ministry of Health and Welfare’s “2025 Korea-ARPA-H Project.”
-
NewsManganese is Lyme disease bacterium’s double-edged sword
For decades, Lyme disease has frustrated both physicians and patients alike. Caused by the corkscrew-shaped bacterium Borrelia burgdorferi, the infection, if left untreated, can linger for months, leading to fever, fatigue and painful inflammation. Source: U.S. Centers for Disease Control and Prevention This digitally colorized scanning electron microscopic ...
-
NewsSingle-dose malaria treatment combining four existing drugs as effective as more onerous multi-day, multi-dose regimen
Hundreds of malaria patients participating in a clinical trial in Gabon in West Africa were cured via a single dose of a treatment that utilizes four widely available malaria drugs, according to a new study.
-
NewsStudy reveals that flu vaccine performance varies by age
New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age of the patient.
-
NewsRepurposed antibiotic shows promise against Central Nervous System Tuberculosis
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study. Published in the Journal of Neuroinflammation, the ...
-
NewsNew drug target identified in fight against resistant infections
Researchers have identified new drug targets within a special repair system possessed by certain bacteria, known as Rtc, which enables them to counteract the effects of these antibiotics.
-
NewsLow-dose cannabis compound reduces side effects of HIV treatment
Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART). Benefits included increased production of serotonin, while inflammation, cholesterol and harmful secondary bile acids were all reduced.
-
NewsBiochemists search for cellular vulnerabilities in killer ‘superbugs’
Helen Zgurskaya and Valentin Rybenkov are leading a five-year, $5.3 million project funded by the National Institute of Allergy and Infectious Diseases to find new ways to deliver lifesaving drugs directly into resistant pathogens.
-
NewsTemporary benefit for immune system in early HIV treatment, but dysregulation returns
A study investigated whether immune dysregulation can be prevented by starting HIV medication immediately after infection. Six months after this early treatment, the immune system did indeed work as in people without HIV, but in the longer term, the immune system was disrupted again.
-
NewsScientists uncover tuberculosis bacterium’s ’heartbeat’, opening door to new treatments
Scientists have identified a molecular system inside Mycobacterium tuberculosis that functions like the organism’s heart or lungs, keeping it alive. The system, known as PrrAB, helps the bacterium generate energy and breathe. When researchers used a gene-silencing tool, the bacterium died.
-
NewsEarly-stage clinical trial demonstrates promise of intranasal influenza vaccine in generating broad immunity
Researchers report encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 ’bird flu’, highlighting the potential of mucosal immunization strategies.
-
NewsAI can speed antibody design to thwart novel viruses: study
Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study
-
NewsNew study finds targets for a new tuberculosis vaccine
A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.
-
NewsBreathing new life Into TB treatment with inhalable nanomedicine
Scientists are developing an inhalable nanosystem to transport TB medicines directly into the lungs, the very place where the bacterium that causes TB hides and thrives. The nanocarrier can hold all four standard TB drugs in a single formulation and release them precisely at the infection site.
-
NewsHorizon Awards 2025: Dr Manu De Rycker named as winner of WH Pierce Prize
Dr Manu De Rycker, a Principal Investigator at the University of Dundee, has been named as the newest winner of the WH Pierce Global Impact in Microbiology Prize.